GALEAS Tumor is an expertly curated NGS panel developed in parallel with bioinformatics pipelines for the comprehensive profiling of solid tumors. It targets 519 carefully selected, clinically relevant genes aligned with the UK NHS national genomic test directory, NCCN, FDA and ESMO guidelines.